Saliva may predict development of Alzheimer’s disease

Saliva may hold the keys to understanding a person’s likelihood of developing Alzheimer’s, even among those who don’t yet have memory and thinking problems associated with the disease. Knowing that Alzheimer’s typically coexists with certain metabolic disorders, Shraddha Sapkota, a neuroscience PhD student at the U of A, along with psychology professor Roger Dixon and … Read more

Depression, behavior changes may be earliest symptoms of Alzheimer’s disease

Depression, behavior changes may start in Alzheimer’s even before memory changes – Depression and other behavior changes may show up in people who will later develop Alzheimer’s disease even before they start having memory problems, reported by researchers in the medical journal of the American Academy of Neurology.

Alzheimer’s related memory loss linked to Neuroligin-1 protein

Cleveland Clinic identifies mechanism in Alzheimer’s-related memory loss — Study uncovers role of Neuroligin-1 protein – Cleveland Clinic researchers have identified a protein in the brain that plays a critical role in the memory loss seen in Alzheimer’s patients. The protein – Neuroligin-1 (NLGN1) – is known to be involved in memory formation; this is the first time it’s been linked to amyloid-associated memory loss.

Vitamin E may slow functional decline in Alzheimer’s Disease patients

Vitamin E May Delay Decline in Mild-to-Moderate Alzheimer’s Disease — Study Shows Benefit in Activities of Daily Living and Savings in Caregiver Time with Vitamin E – A new research suggests that alpha tocepherol, fat-soluble Vitamin E and antioxidant, may slow functional decline (problems with daily activities such as shopping, preparing meals, planning, and traveling) in patients with mild-to-moderate Alzheimer’s disease and decrease caregiver burden.

Buphenyl a possible drug for Alzheimer’s disease

Rush scientists identify buphenyl as a possible drug for Alzheimer’s disease – Buphenyl, an FDA-approved medication for hyperammonemia, may protect memory and prevent the progression of Alzheimer’s disease. Hyperammonemia is a life-threatening condition that can affect patients at any age. It is caused by abnormal, high levels of ammonia in the blood.

Alzheimer disease drug enters into phase II III study

Merck Initiates Phase II/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer’s Disease – Although several pharmaceutical companies in US have experienced setbacks with Alzheimer’s compounds, Merck & Co., Inc. hopes to defy the odds with plans to take a Alzheimer pill into a Phase II/III clinical study with patients who suffer from mild-to-moderate stages of the Alzheimer’s disease.

Binge drinking increases cognitive decline in older adults

Binge drinking increases the risk of cognitive decline in older adults – Researchers from the Peninsula College of Medicine and Dentistry (PCMD), University of Exeter, suggesting a link between binge drinking in older adults and the risk of developing dementia. The work is supported by the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care in the South West Peninsula (NIHR PenCLAHRC).

Do NOT follow this link or you will be banned from the site!